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Health related quality of life outcomes for
unresectable stage III or IV melanoma patients
receiving ipilimumab treatment
Dennis A Revicki1*, Alfons JM van den Eertwegh2, Paul Lorigan3, Celeste Lebbe4, Gerald Linette5,
Christian H Ottensmeier6, Shima Safikhani1, Marianne Messina7, Axel Hoos7, Samuel Wagner8 and Srividya Kotapati7

Abstract
Background: In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival
benefit in previously treated advanced melanoma patients. This report summarizes health-related quality of life
(HRQL) outcomes for ipilimumab with/without gp100 vaccine compared to gp100 alone during the clinical trial’s
12 week treatment induction period.
Methods: The Phase III clinical trial (MDX010-20) was a double-blind, fixed dose study in 676 previously treated
advanced unresectable stage III or IV melanoma patients. Patients were randomized 3:1:1 to receive either
ipilimumab (3 mg/kg q3w x 4 doses) + gp100 (peptide vaccine; 1 mg q3w x 4 doses; ipilimumab plus gp100,
n = 403); gp100 vaccine + placebo (gp100 alone, n = 136); or ipilimumab + placebo (ipilimumab alone, n = 137). The
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
assessed HRQL. Baseline to Week 12 changes in EORTC QLQ-C30 function, global health status, and symptom
scores were analyzed for ipilimumab with/without gp100 vaccine compared to gp100 alone. Mean change in
scores were categorized “no change” (0–5), “a little” (5–10 points), “moderate” (10–20 points), and “very much”
(>20).
Results: In the ipilimumab plus gp100 and ipilimumab alone groups, mean changes from baseline to Week 12
generally indicated “no change” or “a little” impairment across EORTC QLQ-C30 global health status, function, and
symptom subscales. Significant differences in constipation, favoring ipilimumab, were observed (p < 0.05). For
ipilimumab alone arm, subscales with no or a little impairment were physical, emotional, cognitive, social function,
global health, nausea, pain, dyspnea, constipation, and diarrhea subscales. For the gp100 alone group, the observed
changes were moderate to large for global health, role function, fatigue, and for pain.
Conclusions: Ipilimumab with/without gp100 vaccine does not have a significant negative HRQL impact during
the treatment induction phase relative to gp100 alone in stage III or IV melanoma patients.
Trial registration: Clinicaltrials.gov identification number NCT00094653
Keywords: Ipilimumab, Randomized clinical trial, EORTC QLQ-C30, Advanced melanoma, Health-related quality of
life
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Introduction
Advanced melanoma is a serious and life threatening cancer which has an impact on health-related quality of life
(HRQL). According to the American Cancer Society, there
were an estimated 68,130 new cases of melanoma and
8,700 deaths in the US in 2010, which accounts for almost
three-fourths of all skin cancer deaths [1]. The median
overall survival for patients with untreated advanced melanoma ranges between 6 to 9 months [1-6]. Cornish et al.
recently demonstrated that the impact of melanoma on
patient HRQL is comparable with other cancers [7].
Until the recent approvals for vemurafenib and ipilimumab, none of the currently approved treatments for
advanced melanoma have shown overall survival benefit
[3,8-18]. The focus of current treatment is on improving
survival, managing symptoms, and improving HRQL outcomes [2,19]. Studies have shown that melanoma impacts
psychological functioning (i.e., anxiety, depression, and
vulnerability) [20-24]. In studies of advanced melanoma
patients receiving treatment, melanoma patients also
reported significant impairments in physical functioning
and fatigue symptoms [20,25,26]. Treatment-related
HRQL outcomes vary by HRQL instrument, study methods and design, study dropout rates, and disease progression rates. These factors need to be taken into
consideration when interpreting the findings of HRQL
studies in advanced melanoma.
Several clinical trials comparing treatments for advanced
melanoma have included HRQL measures [14,20,26-36].
In general, these clinical studies demonstrate varied
HRQL and symptom effects for different treatments, although the earliest studies demonstrate significant impairment to functioning [34,35]. However, most of these
studies have considerable dropout rates and results are
often restricted to the initial weeks of the clinical trial
study. Dropouts are frequently observed in patients with
significant toxicity or disease progression, and these missing data can make the follow-up HRQL outcomes appear
better than they are in reality [37].
Ipilimumab is an anti-CTLA-4 monoclonal antibody
with anti-tumor activity and has demonstrated statistically
significant improvement in overall survival in a Phase III
study (MDX010-20) in patients with previously treated
unresectable stage III or IV melanoma [9]. Efficacy and
safety data corresponding to the Phase II and III clinical
trials in advanced melanoma have been reported elsewhere [9,12,38]. Overall, ipilimumab, alone or in combination with gp100, was tolerable in subjects with advanced
metastatic melanoma with a generally manageable safety
profile, which is consistent with safety demonstrated in
previous studies of ipilimumab [9]. Study drug-related adverse events, regardless of etiology, were severe (≥ Grade
3) for 19.5%, 26.0%, and 12.1% of subjects treated with ipilimumab plus gp100, ipilimumab alone, and gp100 alone,
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respectively [9]. Immune-related adverse events were the
most frequently reported drug-related adverse events [9].
The immune-related adverse events of ipilimumab are
managed through administration of systemic glucocorticoids and other immunosuppressant agents along with adherence to treatment according to well established
guidelines [39,40]. The majority of these immune-related
adverse events occurred during the induction period of
ipilimumab treatment. This report summarizes the HRQL
outcomes during the 12 week treatment induction period
of the ipilimumab Phase III clinical trial (MDX010-20).
Assessment of the effects of ipilimumab in relation to
overall HRQL is important and will allow oncologists to
appropriately educate patients on the risks and benefits of
treatment with this agent.

Methods
Study design

Study MDX010-20 was conducted in accordance with
International Conference on Harmonisation-Good Clinical Practices and the Declaration of Helsinki. The study
was approved by local regulatory authorities and institutional review boards and Ethics Committees at the participating sites, and all subjects provided written consent.
The Phase III clinical trial (MDX010-20) was a doubleblind, fixed dose study in 676 previously treated patients
with advanced stage III or IV melanoma [9]. Patients in
this trial were randomized 3:1:1 to receive either ipilimumab (3 mg/kg q3w x 4 doses) + gp100 (peptide vaccine;
1 mg q3w x 4 doses; ipilimumab plus gpl00, n = 403);
gp100 vaccine + placebo (gp100 alone, n = 136); or ipilimumab + placebo (ipilimumab alone, n = 137). The main inclusion criteria were men and women aged ≥18 years,
histological confirmed advanced stage III or IV melanoma,
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and life expectancy of at least four
months. Key exclusion criteria included active symptomatic or asymptomatic untreated central nervous system
(CNS) metastasis, primary ocular melanoma, or pregnant
or breastfeeding women. Patients with stable, pre-treated
CNS metastases were allowed in the study.
Treatment regimen

Ipilimumab, at a dose of 3 mg per kilogram of body
weight, was administered with or without gp100 every
three weeks for up to four treatments (induction) [9]. In
the gp100 groups, patients received two modified HLAA* 0201-restricted peptides with incomplete Freund’s
adjuvant (Montanide ISA-51): a gp100:209-217(210M)
peptide, 1 mg injected in the right anterior thigh, and a
gp100:280-288(288V) peptide, 1 mg injected in the left
anterior thigh. These injections were given immediately
after the intravenous infusion of ipilimumab or placebo.
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Treatment was started on day 1 of Week 1, and additional treatment was received at Weeks 4, 7, and 10 if
there was no intolerable toxicity, no rapidly progressive
disease, and no significant decline in performance status.
This included patients who developed new lesions and/or
experienced growth in baseline lesions. Patients were
offered additional courses of therapy (reinduction) if they
had stable disease after Week 12 or a confirmed partial or
complete response and no dose-limiting toxicity, or if they
had disease progression with their assigned treatment
regimen [9].
Health-related quality of life measure

HRQL was evaluated using the European Organization
for Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30) [41,42]. The EORTC
QLQ-C30 contains subscales for global health status,
and physical, emotional, role, cognitive, and social function, with higher scores indicating better functioning
[41,42]. Symptom subscales include pain, nausea/vomiting, fatigue, dyspnea, appetite loss, insomnia, diarrhea,
and constipation (higher scores indicate greater symptom severity). Extensive evidence is available supporting
the reliability, validity, and responsiveness of the EORTC
QLQ-C30 in different cancer populations [42,43]. In the
Phase III trial (MDX010-20), HRQL outcomes were selfadministered at the clinical centers before any clinical
procedures or physician interactions, including any discussion of imaging studies at baseline and Week 12.
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and gp100 alone (n = 136) treatment arms. Participants
from all three arms (total n = 676) had a mean age of
56.2 ± 57.0 years and 59% were male (Table 1). The majority of participants had M1C stage at entry (n = 483;
71.4%) and almost all had an ECOG performance status
score of 0 or 1 (n = 665; 98.4%). All of the participants
had received prior treatment for advanced melanoma.
Twelve percent of participants (n = 82; 12.1%) had CNS
metastases at baseline.
HRQL outcomes

In the Phase III study (MDX010-20), 95% had baseline
HRQL assessments and Week 12 assessments were
available for 236 (62%), 85 (65%), and 80 (61%) of the
patients treated with ipilimumab plus gp100, ipilimumab
alone, and gp100 alone, respectively. Missing HRQL data
at baseline were due to administrative errors. Reasons
for missing Week 12 data were primarily due to disease
progression, adverse events, or death [9]. There were no
differences in demographic or relevant clinical characteristics between those study patients with complete and
missing Week 12 HRQL assessments. There were differences in baseline EORTC QLQ-C30 scores for global,
physical, role, emotional, and social function scores and
for fatigue, nausea, pain, dyspnea, sleep, appetite, and
constipation scores between those with and without
Week 12 assessments.
Table 1 Baseline demographics and clinical characteristics
Phase III (MDX010-20)

Statistical analyses

Baseline to Week 12 changes in EORTC QLQ-C30 function, global health status and symptom scores were calculated. Analysis of variance models were used to compare
treatment differences for the HRQL outcomes. Since there
is clinical interest in effectiveness and risks in older oncology patients, post hoc subgroup analysis of EORTC QLQC30 data by age (<65 years versus ≥65 years) was also
conducted, and these analyses were compared to the
results from the total sample (i.e., combined age group).
Descriptive analyses are reported for the data, and no statistical tests were performed due to the ad hoc nature and
relatively small sample sizes. Interpretations of the mean
change in scores were categorized as “no change” (0–5
points), “a little” (5–10 points), “moderate” (10–20 points),
and “very much” (>20 points), based on Osoba et al. [44].
When function and symptom scores showed either “no
change” or “little change,” they were interpreted as reflecting no or minimal impact on patient HRQL [44].

Results

Ipilimumab Ipilimumab gp100
plus gp100 Alone
Alone

Total

(N = 403)

(N = 137)

(N = 136)

(N = 676)

56.8

57.4

56.2

247 (61)

81 (59)

73 (54)

401 (59)

M0

5 (1.2)

1 (0.7)

4 (2.9)

10 (1.5)

M1a

37 (9.2)

14 (10.2)

11 (8.1)

62 (9.2)

M1b

76 (18.9)

22 (16.1)

23 (16.9)

121 (17.9)

M1c

285 (70.7)

100 (73.0)

98 (72.1)

483 (71.4)

Prior treatment
for advanced
melanoma, n (%)

403 (100.0)

137 (100.0)

136 (100.0) 676 (100.0)

0

233 (57.8)

72 (52.6)

70 (51.5)

1

165 (40.9)

64 (46.7)

61 (44.9)

290 (42.9)

2 or 3

5 (1.2)

1 (0.7)

4 (2.9)

10 (1.4)

Age (years), mean 55.6
Gender, n (%)
Male
Melanoma stage,
n (%)

ECOG PS, n (%)
375 (55.5)

Demographic and clinical characteristics

Missing

0

0

1 (0.7)

1 (0.1)

Patients were randomly assigned to either the ipilimumab plus gp100 (n = 403), ipilimumab alone (n = 137),

CNS metastases
at baseline, n (%)

46 (11.4)

15 (10.9)

21 (15.4)

82 (12.1)
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When HRQL outcomes were evaluated, most observed
baseline to Week 12 changes were no greater than minimal
in the “a little” impairment category (Figures 1 and 2).
There was a statistically significant difference in constipation scores between the ipilimumab plus gp100 and the
gp100 alone groups (p < 0.05) and between the ipilimumab
alone and gp100 alone groups (p < 0.05). None of the other
differences in HRQL scores between the three treatments
were statistically significant.
For the ipilimumab plus gp100 arm, the observed impairments were in the “no change” or “a little” categories for
physical, role, emotional, cognitive, and social function, global health, nausea, pain, dyspnea, sleep disturbance, appetite
loss, constipation, and diarrhea subscales. For the ipilimumab alone group, the observed impairments were in the
“no change” or “a little” categories for the physical, emotional, cognitive, and social function, the global health, nausea, pain, dyspnea, constipation, and diarrhea subscales. For
the gp100 alone group, the observed impairments were in
the “no change” or “a little” categories for the cognitive and
social function, nausea, dyspnea, and diarrhea subscales. In
the gp100 alone group, moderate to large impairments were
seen for global health, role function, fatigue, and pain.
Due to interest from clinicians in the analysis of
results for older oncology patients, results from the post
hoc subgroup analysis of EORTC QLQ-C30 data were
also compared by two age groups: patients aged
<65 years and those ≥65 years (Table 2). For patients
<65 years, in the ipilimumab plus gp100 arm, there were
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none to small impairments in functional outcomes and
symptom scores, while the older age group reported a
similar pattern of changes for most of the outcomes.
Older patients reported moderate impairments in role
function, global health, fatigue and sleep disturbance. In
the ipilimumab alone subgroup of patients <65 years,
the impairment changes in functional outcomes and
symptom scores were none to small for most scores, except for fatigue and appetite loss. For patients aged
≥65 years, in the ipilimumab alone group, moderate or
greater impairments were seen in social function and
global health, which differed somewhat from the younger
age group. More symptom effects were observed in those
≥65 years for dyspnea and diarrhea compared with the
<65 age group. These findings need to be interpreted cautiously given the smaller sample size.

Discussion
Ipilimumab at 3 mg/kg monotherapy, whether combined
with gp100 vaccine or not, was associated with a 19% to
36% reduction in the rate of disease progression and,
more importantly, had increased overall survival compared with the gp100 vaccine alone group in patients
with previously treated advanced melanoma [9]. In general, the HRQL results for the ipilimumab groups demonstrate that ipilimumab treatment is associated with
minimal impairments on functioning and symptoms
during the treatment induction period. The only statistically significant difference between ipilimumab and

Figure 1 Baseline to Week 12 endpoint changes in EORTC QLQ-C30 function and global health status scores. * For the functioning and
global health scales, improvements are indicated by positive scores. ** p > 0.05 for all comparisons. Mean change in scores were categorized as
“no change” (0–5), “a little” (5–10 points), “moderate” (10–20 points), and “very much” (>20).
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Figure 2 Baseline to Week 12 endpoint changes in EORTC QLQ-C30 symptom scores. * For symptom scales, improvements are indicated
by negative scores. ** p < 0.05 versus gp100 group. *** p > 0.05 for all comparisons (except for Constipation with p < 0.05). Mean change in
scores were categorized as “no change” (0–5), “a little” (5–10 points), “moderate” (10–20 points), and “very much” (>20).

gp100 vaccine was for constipation, and this finding may
be due to increased rate of colitis in the ipilimumab
groups (5.3-7.6% versus 0.8%) [9]. Most of the observed
changes were in the range of “no change” or minimal
impairments, which indicates that HRQL was maintained during the treatment induction period. Functioning and symptom scores did not improve during
treatment; only the overall HRQL of these patients was
negatively impacted to a small extent. The gp100 group

reported increased pain, fatigue, dyspnea, and decreased
physical and role function compared with the ipilimumab group.
After 12 weeks of treatment with ipilimumab, only fatigue, sleep disturbance, and appetite loss showed moderate impairments. However, there was no significant
negative impact on physical, emotional, cognitive, and
social functioning and global health status in the ipilimumab treated groups. These findings indicate that

Table 2 Baseline to week 12 endpoint changes in EORTC QLQ-C30 scores by age groups
Ipilimumab plus gp100
< 65 years

Ipilimumab plus gp100
≥ 65 years

Ipilimumab Alone

Ipilimumab Alone

< 65 years

≥ 65 years

(N = 170)

(N = 66)

(N = 59)

(N = 26)

Physical function

−6.2

−9.5

−4.3

−9.3

Role function

−9.8

−11.7

−11

−12.9

Emotional function

−0.8

−6.2

−2.2

−9.3

Cognitive function

−3.9

−4.7

−3.6

−8.8

Social function

−5.4

−7.4

−6

−12.3

Global health

−6.5

−12.1

−6

−17

Fatigue

9

14.2

12.4

12.1

Nausea/vomiting

5.3

7.3

4.9

3.1

Pain

7.2

6.4

10

7.4

Dyspnea

2

8.1

2.1

12.5

Sleep disturbance

5

10.4

8.8

12.9

Appetite loss

9.4

9.6

12.9

11.7

Constipation

3.8

6

2.3

−0.4

Diarrhea

6.2

7.7

7.7

13.5
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HRQL outcomes were minimally impaired by ipilimumab treatment. Therefore, the trade-offs between
extended survival and HRQL may be acceptable to
patients and their clinicians [45]. Given that few treatments for advanced melanoma (i.e., vemurafenib and ipilimumab) are associated with improvements in overall
survival [9,10,12,13], these HRQL results for ipilimumab
are very encouraging.
We identified three studies that used the EORTC
QLQ-C30 comparing treatments for advanced melanoma [14,32,34]. Study design and methods are summarized in Additional file 1 Table A1. Two of these studies
reported higher rates of missing HRQL data at followup compared with ipilimumab plus gp100 or ipilimumab alone (Additional file 1 Table A2). Disease progression rates were somewhat greater in the comparison
studies, ranging from 61% to 74% (Additional file 1
Table A2). For the EORTC QLQ-C30 functional outcomes, dacarbazine-videsine-cisplatin and dacarbazinevidesine treated groups demonstrated worse global health
and physical, role, and social function compared with ipilimumab plus gp100 or ipilimumab alone groups (Additional
file 2 Figure A1). For the symptom outcomes, dacarbazinevidesine-cisplatin and dacarbazine-videsine treated
groups demonstrated worse fatigue, nausea/vomiting,
and appetite loss and similar pain compared with ipilimumab plus gp100 and ipilimumab alone groups (Additional
file 3 Figure A2). The studies by Avril et al. [14] and
Kiebert et al. [32] showed changes in EORTC QLQ-C30
function and symptom scores comparable to the ipilimumab plus gp100 and ipilimumab alone treatment groups.
Overall, the ipilimumab HRQL effects we observed may
be better or comparable to those observed in these other
clinical trials, as supported by little meaningful impairment in functioning and symptoms during the treatment
induction period.
The comparison of HRQL outcomes between the ipilimumab clinical trials and these other studies should be
interpreted cautiously given the differences in methods,
disease progression, and dropout rates. Significant differences in mechanism of action and known toxicity profiles of chemotherapy and ipilimumab may contribute to
observed differences in HRQL between the chemotherapy and ipilimumab. In addition, ipilimumab’s demonstrated efficacy compared to the general lack of
chemotherapy activity in this disease is another consideration for observed differences.
In the Phase II study for ipilimumab [38], mean
changes from baseline to Week 12 for the 3 mg/kg arm
generally indicated little or no negative impact to patient
HRQL across the EORTC QLQ-C30 subscales for global
health status, function, and symptoms. These Phase II
results are similar to the Phase III (MDX010-20) results
and add further support to the effects of ipilimumab
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treatment as possibly better or comparable to those
observed in these other clinical trials.
Clinicians are concerned about the effects of treatment
on elderly (i.e., ≥65 years of age) advanced melanoma
patients [46,47]. Although overall survival is comparable
for patients aged <65 and ≥65 years (for ipilimumab
plus gp100 versus gp100 alone, hazard ratio was 0.70
and 0.69 for <65 years and ≥65 years, respectively; for
ipilimumab alone versus gp100 alone, hazard ratio was
0.65 and 0.61 for <65 years and ≥65 years, respectively)
[9], we evaluated differences in HRQL outcomes by age
group. For the ipilimumab plus gp100, results were comparable for both age groups, although those ≥65 years
reported more impairment in role function, global
health, and sleep disturbance. For the ipilimumab alone
groups, the results for functional outcome and symptom
scores were comparable, except that those ≥65 years
reported more impairment in social function, dyspnea,
sleep disturbance, and diarrhea.
The HRQL results from the current ipilimumab study
should be interpreted considering the following limitations. HRQL endpoint data were available for only 61% to
65% of patients randomized into the clinical trial. Disease
progression was the most common reason for discontinuation of study drug (24% of subjects in the ipilimumab
plus gp100 group; 16% in the ipilimumab alone group;
and 33% in the gp100 alone group). Rates of discontinuation of study drug due to adverse events were greatest for
ipilimumab alone (13%) compared with ipilimumab plus
gp100 (9%) and gp100 alone (4%). However, there were
comparable completion rates of the EORTC QLQ-C30
across treatment arms in the current study (MDX010-20),
so these missing data may not impact the interpretation of
the HRQL results. Missing HRQL data is a significant
problem for oncology studies, and patients who complete
follow-up assessments are less likely to experience severe
toxicity and are more likely to have better response to
treatment [37]. Finally, although EORTC QLQ-C30 is an
internationally validated, widely used questionnaire for
assessing the HRQL in oncology, melanoma specific
HRQL questions might not have been addressed.

Conclusions
In conclusion, ipilimumab at 3 mg/kg with and without
gp100 vaccine does not have a significant negative impact on HRQL in patients completing the baseline and
Week 12 follow-up, during the treatment induction
phase compared with gp100 alone. Ipilimumab treatment results in little to no impairment in HRQL outcomes in advanced melanoma patients. The improved
survival observed in the ipilimumab treated groups does
not come with a significant burden on HRQL for
patients in this analysis. Further research is needed to
determine the long term impact of ipilimumab treatment
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on HRQL outcomes. In addition, further analyses are
needed to better understand the impact of serious adverse
events on HRQL in ipilimumab treated patients.

Page 7 of 8

06492, USA. 8Bristol-Myers Squibb, 100 Nassau Park Boulevard, Princeton,
NJ08540, USA.
Received: 23 November 2011 Accepted: 17 May 2012
Published: 13 June 2012

Additional files
Additional file 1: Methodology for comparison with other melanoma
clinical trials. A systematic search of review articles and clinical trial
articles was conducted in order to compare the HRQL findings from the
ipilimumab studies to other published clinical trials in advanced
melanoma that included the EORTC QLQ-C30. Microsoft Word document
file name: HRQL Melanoma Manuscript Appendix_HQLO_final.doc.
Additional file 2: Figure A1. Baseline to endpoint changes in EORTC
QLQ-C30 function and global health scores for advanced melanoma
studies.
Additional file 3: Figure A2. Baseline to endpoint changes in EORTC
QLQ-C30 symptom scores for advanced melanoma studies.
Abbreviations
CNS: Central Nervous System; DTIC: Dacarbazine; ECOG: Eastern Cooperative
Oncology Group; EORTC QLQ-C30: European Organization for Research and
Treatment of Cancer Quality of Life Core Questionnaire; FACT: Functional
Assessment of Cancer Therapy; HRQL: Health-Related Quality of Life;
I.V.: Intravenous.
Competing interests
DAR and SS are employees of United BioSource Corporation and have
research support from Bristol-Myers Squibb (BMS). AJMV is on the BMS
advisory board and has been paid honoraria by BMS. PL is a consultant to
BMS, has been a member of BMS Speakers Bureau, and has received
honoraria from BMS to attend international conferences. PL has undertaken
a number of unpaid academic projects with BMS around treatment of
melanoma and also this study; which have been or are being submitted for
publication. CL has received honoraria from BMS for ipilimumab
development. GL is a consultant for GlaxoSmithKline, Genentech, and BMS
and has received honoraria from BMS. CHO has consulted for BMS, received
honoraria from BMS, and has received an unrestricted grant from BMS for a
clinical trial using ipilimumab. MM declares that she has no competing
interests. AH is an employee with BMS, holds a leadership position with the
Cancer Immunotherapy Consortium, and owns stocks in BMS. SW is an
employee with and owns stock in BMS. SK is an employee with, owns stock
in, and has research funding from BMS.
Authors' contributions
DAR participated in data analysis and interpretation and manuscript writing.
AJMV participated in data analysis and interpretation and manuscript writing.
PL participated in the collection and assembly of data, data analysis and
interpretation, and manuscript writing. CL participated in the conception and
design and manuscript writing. GL participated in data analysis and
interpretation and manuscript writing. CHO participated in the conception
and design and manuscript writing. SS participated in manuscript writing
and provided project management and administrative support. MM
participated in data analysis and interpretation and manuscript writing. AH
participated in data analysis and interpretation and manuscript writing. SW
participated in conception and design and manuscript writing. SK
participated in the conception and design, collection and assembly of data
and manuscript writing. All authors read and approved the final manuscript.
Author details
1
United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, Bethesda,
MD 20814, USA. 2VU University Medical Center, Boelelaan 1117 1081HV,
Amsterdam, The Netherlands. 3University of Manchester, Christie NHS
Foundation Trust Wilmslow Road, Manchester M20 4BX, UK. 4Hôpital St.
Louis, APHP Dermatology University Paris 7, Diderot, France. 5Division of
Oncology, Washington University School of Medicine, 660 S, Euclid Avenue,
Campus Box 8056, St. Louis, MO 63110, USA. 6Southampton University and
University Hospital Southampton, Cancer Sciences Division, Southampton
O16 6YD, UK. 7Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT

References
1. American Cancer Society: Cancer Facts & Figures 2010. Atlanta: American
Cancer Society; 2010.
2. Tsao H, Atkins MB, Sober AJ: Management of cutaneous melanoma. N
Engl J Med 2004, 351:998–1012.
3. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick
AC, DeConti R, Hersh EM, Hersey P, et al: Bcl-2 antisense (oblimersen
sodium) plus dacarbazine in patients with advanced melanoma: the
Oblimersen Melanoma Study Group. J Clin Oncol 2006, 24:4738–4745.
4. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS,
Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, et al: Phase III
multicenter randomized trial of the Dartmouth regimen versus
dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999,
17:2745–2751.
5. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M,
Aamdal S, Cebon J, Coates A, et al: Randomized phase III study of
temozolomide versus dacarbazine in the treatment of patients with
advanced metastatic malignant melanoma. J Clin Oncol 2000, 18:158–166.
6. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J,
Sondak VK, Atkins MB, Eisenhauer EA, et al: Meta-analysis of phase II
cooperative group trials in metastatic stage IV melanoma to determine
progression-free and overall survival benchmarks for future phase II
trials. J Clin Oncol 2008, 26:527–534.
7. Cornish D, Holterhues C, van de Poll-Franse LV, Coebergh JW, Nijsten T: A
systematic review of health-related quality of life in cutaneous
melanoma. Ann Oncol 2009, 20(suppl 6):vi51–vi58.
8. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J,
Sznol M, Parkinson D, Hawkins M, et al: High-dose recombinant
interleukin 2 therapy for patients with metastatic melanoma: analysis of
270 patients treated between 1985 and 1993. J Clin Oncol 1999,
17:2105–2116.
9. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB,
Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al: Improved survival
with ipilimumab in patients with metastatic melanoma. N Engl J Med
2010, 363:711–723.
10. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J,
Dummer R, Garbe C, Testori A, Maio M, et al: Improved survival with
vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med
2011, 364:2507–2516.
11. Trinh VA: Current management of metastatic melanoma. Am J Health Syst
Pharm 2008, 65(suppl 9):S3–S8.
12. Robert C, Thomas L, Bondarenko I, O'Day S, DJ M, Garbe C, Lebbe C, Baurain
JF, Testori A, Grob JJ, et al: Ipilimumab plus dacarbazine for previously
untreated metastatic melanoma. N Engl J Med 2011, 364:2517–2526.
13. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur
GA, Hutson TE, Moschos SJ, Flaherty KT, et al: Survival in BRAF V600mutant advanced melanoma treated with vemurafenib. N Engl J Med
2012, 366:707–714.
14. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal
M, Neuber K, Bieber T, Gilde K, et al: Fotemustine compared with
dacarbazine in patients with disseminated malignant melanoma: a
phase III study. J Clin Oncol 2004, 22:1118–1125.
15. Patel P, Suciu S, Mortier L, Kruit W, Robert C, Schadendorf D, Keilholz E,
Musat A, Eggermont A, Spatz: Extended schedule, escalated dose
temozlomide versus dacarbazine in stage IV malignant melanoma: final
results of the randomised phase III study (EORTC 18032). Ann Oncol 2008,
19. Abstract LB8.
16. Ribas A, Hauschild A, Kefford R, Gomez-Navarro J, Pavlov D, Marshall MA:
Phase III, open-label, randomized, comparative study of tremelimumab
(CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine
[DTIC]) in patients with advanced melanoma. J Clin Oncol 2008, 26.
Abstract LBA9011.
17. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber
DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, et al: Prospective
randomized trial of high-dose interleukin-2 alone or in conjunction with

Revicki et al. Health and Quality of Life Outcomes 2012, 10:66
http://www.hqlo.com/content/10/1/66

18.

19.

20.

21.
22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

lymphokine-activated killer cells for the treatment of patients with
advanced cancer. J Natl Cancer Inst 1993, 85:622–632.
Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins
MB, Dutcher JP, Micetich KC, Weiss GR, et al: Randomized phase III trial of
treatment with high-dose interleukin-2 either alone or in combination
with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol
1993, 11:1969–1977.
Food and Drug Administration: Guidance for industry on clinical trial
endpoints for the approval of cancer drugs and biologics. Fed Regist
2007, 72:27575–27576.
Trask PC, Paterson AG, Esper P, Pau J, Redman B: Longitudinal course of
depression, fatigue, and quality of life in patients with high risk melanoma
receiving adjuvant interferon. Psychooncology 2004, 13:526–536.
Boyle DA: Psychological adjustment to the melanoma experience. Semin
Oncol Nurs 2003, 19:70–77.
Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S: The
prevalence of psychological distress by cancer site. Psychooncology 2001,
10:19–28.
Derogatis LR, Morrow GR, Fetting J, Penman D, Piasetsky S, Schmale AM,
Henrichs M, Carnicke CL Jr: The prevalence of psychiatric disorders
among cancer patients. JAMA 1983, 249:751–757.
Vurnek M, Buljan M, Situm M: Psychological status and coping with
illness in patients with malignant melanoma. Coll Antropol 2007,
31(Suppl 1):53–56.
Cohen L, Parker PA, Sterner J, De Moor C: Quality of life in patients with
malignant melanoma participating in a phase I trial of an autologous
tumour-derived vaccine. Melanoma Res 2002, 12:505–511.
Bender CM, Yasko JM, Kirkwood JM, Ryan C, Dunbar-Jacob J, Zullo T:
Cognitive function and quality of life in interferon therapy for
melanoma. Clin Nurs Res 2000, 9:352–363.
Kienle GS, Kiene H: Review article: Influence of Viscum album L (European
mistletoe) extracts on quality of life in cancer patients: a systematic
review of controlled clinical studies. Integr Cancer Ther 2010, 9:142–157.
Cashin RP, Lui P, Machado M, Hemels ME, Corey-Lisle PK, Einarson TR:
Advanced cutaneous malignant melanoma: a systematic review of
economic and quality-of-life studies. Value Health 2008, 11:259–271.
Cormier JN, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Camacho LH,
Kim K, Webster K, Cella D, Palmer JL: Prospective assessment of the
reliability, validity, and sensitivity to change of the Functional
Assessment of Cancer Therapy-Melanoma questionnaire. Cancer 2008,
112:2249–2257.
Quirt I, Verma S, Petrella T, Bak K, Charette M: Temozolomide for the
treatment of metastatic melanoma: a systematic review. Oncologist 2007,
12:1114–1123.
Paterson AG, Trask PC, Wagner LI, Esper P, Redman B: Validation of the
FACT-BRM with interferon-alpha treated melanoma patients. Qual Life Res
2005, 14:133–139.
Kiebert GM, Jonas DL, Middleton MR: Health-related quality of life in
patients with advanced metastatic melanoma: results of a randomized
phase III study comparing temozolomide with dacarbazine. Cancer Invest
2003, 21:821–829.
Young AM, Marsden J, Goodman A, Burton A, Dunn JA: Prospective
randomized comparison of dacarbazine (DTIC) versus DTIC plus
interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R Coll
Radiol) 2001, 13:458–465.
Sigurdardottir V, Bolund C, Sullivan M: Quality of life evaluation by the
EORTC questionnaire technique in patients with generalized malignant
melanoma on chemotherapy. Acta Oncol 1996, 35:149–158.
Chiarion-Sileni V, Del Bianco P, De Salvo GL, Lo Re G, Romanini A, Labianca
R, Nortilli R, Corgna E, Dalla Palma M, Lo Presti G, Ridolfi R: Quality of life
evaluation in a randomised trial of chemotherapy versus biochemotherapy in advanced melanoma patients. Eur J Cancer 2003,
39:1577–1585.
Beusterien KM, Ackerman SJ, Plante K, Glaspy J, Naredi P, Wood D, Gehlsen K,
Agarwala SS: The health-related quality-of-life impact of histamine
dihydrochloride plus interleukin-2 compared with interleukin-2 alone in
patients with metastatic melanoma. Support Care Cancer 2003, 11:304–312.
Fairclough DL: Summary measures and statistics for comparison of
quality of life in a clinical trial of cancer therapy. Stat Med 1997,
16:1197–1209.

Page 8 of 8

38. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W,
Schadendorf D, Smylie M, Guthrie T Jr, et al: Ipilimumab monotherapy in
patients with pretreated advanced melanoma: a randomised, doubleblind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010,
11:155–164.
39. Weber J: Review: anti-CTLA-4 antibody ipilimumab: case studies of
clinical response and immune-related adverse events. Oncologist 2007,
12:864–872.
40. Weber J: Ipilimumab: controversies in its development, utility and
autoimmune adverse events. Cancer Immunol Immunother 2009,
58:823–830.
41. European Organisation for Research and Treatment of Cancer: European
Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30). Brussels: European Organisation for
Research and Treatment of Cancer; [cited 2012 May]; Available from: http://
groups.eortc.be/qol/questionnaires_qlqc30.htm.
42. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti
A, Flechtner H, Fleishman SB, de Haes JC, et al: The European Organization
for Research and Treatment of Cancer QLQ-C30: a quality-of-life
instrument for use in international clinical trials in oncology. J Natl
Cancer Inst 1993, 85:365–376.
43. Osoba D, Aaronson N, Zee B, Sprangers M, te Velde A: Modification of the
EORTC QLQ-C30 (version 2.0) based on content validity and reliability
testing in large samples of patients with cancer. The Study Group on
Quality of Life of the EORTC and the Symptom Control and Quality of
Life Committees of the NCI of Canada Clinical Trials Group. Qual Life Res
1997, 6:103–108.
44. Osoba D, Rodrigues G, Myles J, Zee B, Pater J: Interpreting the significance
of changes in health-related quality-of-life scores. J Clin Oncol 1998,
16:139–144.
45. Lipscomb J, Reeve BB, Clauser SB, Abrams JS, Bruner DW, Burke LB, Denicoff
AM, Ganz PA, Gondek K, Minasian LM, et al: Patient-reported outcomes
assessment in cancer trials: taking stock, moving forward. J Clin Oncol
2007, 25:5133–5140.
46. Lichtman SM: Guidelines for the treatment of elderly cancer patients.
Cancer Control 2003, 10:445–453.
47. Testori A, Soteldo J, Sances D, Mazzarol G, Trifiro G, Zonta M, Rastrelli M,
Schenone F, Verrecchia F: Cutaneous melanoma in the elderly. Melanoma
Res 2009, 19:125–134.
doi:10.1186/1477-7525-10-66
Cite this article as: Revicki et al.: Health related quality of life outcomes
for unresectable stage III or IV melanoma patients receiving ipilimumab
treatment. Health and Quality of Life Outcomes 2012 10:66.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

